Table 2.
Case/number (%) | Model 1 | Model 2 | Model 3 | |
---|---|---|---|---|
Serum FT4 | ||||
Tertile 1 | 47/699 (6.7) | 1.00 | 1.00 | 1.00 |
Tertile 2 | 60/701 (8.6) | 1.28 (0.86–1.91) | 1.26 (0.83–1.91) | 1.24 (0.82–1.88) |
Tertile 3 | 91/703 (12.9) | 1.97 (1.36–2.86) | 1.91 (1.30–2.81) | 1.88 (1.27–2.77) |
P for trend | <0.0001 | 0.0003 | 0.0008 | 0.001 |
Each 1-pmol/l increase in FT4 | 198/2103 (9.4) | 1.13 (1.05–1.21) | 1.12 (1.04–1.20) | 1.12 (1.05–1.20) |
Serum FT3 | ||||
Tertile 1 | 65/687 (9.5) | 1.00 | 1.00 | 1.00 |
Tertile 2 | 68/712 (9.6) | 1.07 (0.74–1.53) | 1.11 (0.76–1.62) | 1.12 (0.76–1.63) |
Tertile 3 | 65/704 (9.2) | 1.09 (0.75–1.59) | 1.06 (0.72–1.57) | 1.04 (0.70–1.54) |
P for trend | 0.88 | 0.64 | 0.76 | 0.86 |
Each 1-pmol/l increase in FT3 | 198/2103 (9.4) | 1.23 (1.01–1.49) | 1.21 (0.99–1.49) | 1.20 (0.98–1.47) |
Serum TSH | ||||
Tertile 1 | 64/700 (9.1) | 1.00 | 1.00 | 1.00 |
Tertile 2 | 74/700 (10.6) | 1.13 (0.79–1.61) | 1.31 (0.90–1.90) | 1.34 (0.92–1.94) |
Tertile 3 | 60/703 (8.5) | 0.86 (0.59–1.26) | 0.99 (0.66–1.47) | 1.04 (0.69–1.56) |
P for trend | 0.70 | 0.45 | 0.99 | 0.80 |
Each 1-μIU/ml increase in TSH | 198/2103 (9.4) | 0.99 (0.91–1.07) | 0.99 (0.92–1.07) | 1.00 (0.94–1.07) |
Model 1: adjusted for age, sex, BMI at baseline
Model 2: further adjusted for triglyceride, HDL-c, diabetes and hypertension status, current smoking and drinking status, use of antihypertensive drugs, use of antidiabetic drugs, urinary ACR, eGFR at baseline
Model 3: further adjusted for TPOAb, TGAb at baseline
P for trend values for percentages of incident CKD are calculated by using Cochran–Mantel–Haenszel (CMH) method
Data are odds ratios (95% confidence intervals)
ACR albumin-to-creatinine ratio, BMI body mass index, CKD chronic kidney disease, eGFR estimated glomerular filtration rate, FT3 free triiodothyronine, FT4 free thyroxine, HDL-c high-density lipoprotein cholesterol, TSH thyroid-stimulating hormone, TPOAb thyroid peroxidase antibody, TGAb thyroglobulin antibody